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X-linked megalocornea (MGC1) is an ocular anterior segment disorder characterized by an increased cornea diameter and deep anterior
chamber evident at birth and later onset of mosaic corneal degeneration (shagreen), arcus juvenilis, and presenile cataracts. We identi-
fied copy-number variation, frameshift, missense, splice-site and nonsense mutations in the Chordin-like 1 gene (CHRDL1) on Xq23 as
the cause of the condition in seven MGC1 families. CHRDL1 encodes ventroptin, a bone morphogenic protein antagonist with
a proposed role in specification of topographic retinotectal projections. Electrophysiological evaluation revealed mild generalized
cone system dysfunction and, in one patient, an interhemispheric asymmetry in visual evoked potentials. We show that CHRDL1 is ex-
pressed in the developing human cornea and anterior segment in addition to the retina. We explored the impact of loss of ventroptin
function on brain function and morphology in vivo. CHRDL1 is differentially expressed in the human fetal brain, and there is high
expression in cerebellum and neocortex. We show that MGC1 patients have a superior cognitive ability despite a striking focal loss
of myelination of white matter. Our findings reveal an unexpected requirement for ventroptin during anterior segment development
and the consequences of a lack of function in the retina and brain.Introduction
Anterior segment dysgenesis describes a range of pheno-
types caused by failure of normal development of the ante-
rior segment of the eye.1 These anomalies are often associ-
ated with an increased risk of glaucoma, corneal opacity,
and loss of vision. X-linked megalocornea (MGC1 [MIM
309300]), a bilateral and developmental anomaly of the
anterior segment of the eye, is characterized by a thin
cornea of increased diameter (generally>12.5mm at birth)
and a very deep anterior chamber but no increase in intra-
ocular pressure.2 In older patients, MGC1 is associated
with distinctive secondary changes of mosaic corneal
degeneration (shagreen) and corneal arcus juvenilis. Path-
ological changes also include mild iris atrophy with
pigment dispersion, lens dislocation, and cataracts.2,3
Corneal endothelial cells have a normal morphology and
cell density, which suggests that corneal endothelial cell
hyperplasia occurs concurrently with excessive corneal
growth.4
MGC1 was mapped over 20 years ago to Xq12-q26;
however, disease gene identification was hampered
because of the size of the interval (~24.3 Mb).2,5,6 Here
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protein (ventroptin) in anterior segment development.Subjects and Methods
X-Linked Megalocornea Families and Ophthalmic
Clinical Assessment
GenomicDNAwas isolated fromperipheral blood fromtheaffected
individuals and their family members. Informed consent was ob-
tained from all participating families and subjects. This study fol-
lowed the tenets of the Declaration of Helsinki (1983 revision)
and was approved by the local ethics committees. Studies for fami-
lies 1, 2, 3, 4, and 5 were approved by Moorfields Eye Hospital
Research ethics committee, for family 6 by the Cleveland Clinic,
and for family 7 by the Royal Victorian Eye and Ear Hospital.
Informed consent, including permission to publish photographs,
was obtained from all subjects. Patients and their relatives were
clinically assessedbyexperiencedophthalmologists. Standardeval-
uation consisted of detailed ophthalmic examination and the addi-
tional measurement of the axial length of the eye and imaging of
the anterior segment of the eye performed with ocular coherence
tomography (OCT; Visante, Carl ZeissMeditec), b-scan ultrasonog-
raphy, and optical interferometry (IOLMaster, Carl Zeiss Meditec).
The details of the clinical assessment of family 7 are described else-
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detailed retinal and optic nerve head imaging. Color fundus
photography, spectral domain optical coherence tomography
(Spectralis OCT Heidelberg Retina Angiograph), scanning laser
polarimetry (GDxPRO, Carl Zeiss Meditec), and confocal scanning
laser ophthalmoscopy (Heidelberg Retina Tomograph)were under-
taken in individuals II:1 and II:3 in family 1, and II:1 in family 5.
Electrophysiological assessment included full-field and pattern
electroretinography andvisual evoked cortical potentials. Full-field
electroretinography (ERG) was performed with protocols that ex-
ceeded the minimum standards of the International Society for
Clinical Electrophysiology of Vision. Cortical visual evoked poten-
tials (VEPs) were recorded to flash stimuli and high-contrast check-
erboard reversal (check size 0.83 degrees) with multichannel
recordings that otherwise followed the international standards.7,8
Comparative Genomic Hybridization and Mutation
Analysis
DNA for affected individual II:1 from family 1 was hybridized
(labeled with Cy3) to a dense X chromosome array (median probe
spacing of 1 per 340 bp, NimbleGen Systems) with a reference
male DNA sample (labeled with Cy5). The data were visualized
with SignalMap software (NimbleGen Systems). Primers were de-
signed to amplify and bidirectionally sequence exons and exon/
intron boundaries of the CHRDL1 gene (primers available on
request). ReddyMix PCR Master Mix (Abgene, Thermo Scientific)
was used for amplification with 2 pmol of each primer and 150 ng
DNAwith standard cycling conditions. PCR products were purified
with ExoSAP- IT (USB) according to the manufacturer’s protocols.
Purified products were bidirectionally sequenced with ABI BigDye
terminator cycle sequencing chemistry version 3.1 on a 3730 ABI
Analyzer (Applied Biosystems) following themanufacturer’s proto-
cols. PatientDNAsequenceswere analyzedwith Lasergene software
(DNASTAR). None of the mutations identified were listed in either
dbSNP or the 1000 Genomes Project database. To further verify
that themutations identifiedwerenotpolymorphisms, 220 control
male DNA samples were tested with specific primer pairs incorpo-
rating the mutation detected (primers available on request). The
breakpoints of the segmental deletion detected by aCGH for family
1were identifiedbyPCRamplificationacross thedeletionanddirect
sequencing (primers available on request). The extent of the dele-
tion encompassing theCHRDL1 gene in family 7was refined by tar-
geted proximal and distal PCR (primers available on request).
Genetic locations are based on hg19 genome assembly build
(UCSC). Protein sequence alignmentswere performed byClustalW.
Reverse Transcription PCR
RNA was extracted from microdissected human adult corneas and
trabecular meshwork and fetal cornea and whole eyes with Trizol
reagent (Invitrogen) according to the manufacturer’s protocol.
First-strand cDNA synthesis was performed with 50 ng total RNA
via M-MLV Reverse Transcriptase (Promega) and random hexamer
oligonucleotide primers. Second strand synthesis was performed
with gene-specific primers from exon 3 to exon 4 (flanking an
intron) for CHRDL1, 50-AGATGGCATCCTTACCTGGA-30 and
50-ATGCACAGGAGAAAGGCAAT-30, and exon 9 to exon 10 for
PAX6, 50- CACCAGTGTCTACCAACCAA-30 and 50- TTGCATAGG
CAGGTTATTTG-30.
In Situ Hybridization
Human fetal eyes were fixed in 4% (w/v) phosphate-buffered form-
aldehyde solution and equilibrated in 30% sucrose solution for248 The American Journal of Human Genetics 90, 247–259, Februarycryoprotection prior to freezing in an optimal cutting temperature
compound (RA Lamb). Sections were cut on a Leica CM1900 UV
cryostat to 14 mm thickness and collected on Superfrost-Plus glass
slides (VWR). In situ hybridization was performed in 200 mM
NaCl, 5mM EDTA, 10mM Tris-HCl, 5mM sodium phosphate,
0.1mg/ml yeast tRNA, 10% dextran sulfate, 13 Denhardt’s
reagent, and 50% formamide with digoxigenin-incorporated
riboprobes. Riboprobes were generated from a 627 bp fragment
of the 30untranslated region of human CHRDL1 amplified with
the primers 50-CTGGACTGCAGGCTTATTTT-30 and 50-ATTTACT
CTCCTGGGCACAA-30 (probe 1) or with a 777 bp fragment of
the 30 end of the coding region amplified with the primers
50-GCATGGACAAGTGTGTGTTT 30 and 50-ACACACCACTCCA
CACAAAG 30 (probe 2) and cloned into pGEMT-Easy (Promega).
Sections from five eyes at Carnegie stage fetal week 1 (F1) were
analyzed. Both riboprobes gave the same results; data are shown
for probe 1 only. For antibody detection, slides were incubated
with anti-digoxigenin conjugated with alkaline phosphatase
(Roche) diluted 1:1,000 in 2% sheep serum. Expression patterns
were visualized with a Nitro-Blue Tetrazolium Chloride/5-Bromo-
4-Chloro-30-Indolyphosphate p-Toluidine Salt (NBT/BCIP) system
(Roche). Sections were mounted in DPX mounting medium (RA
Lamb) and viewed on a Zeiss Axioplan 2 and images were captured
with a Jenoptik C14 digital camera (OpenLab, Improvision).Association Study
To determine whether gender or common variants within the
CHRDL1 gene influence corneal diameter in the general popula-
tion, we examined a cohort of 20- to 21-year-old young adults,
of whom 88% were white, ascertained for the Raine Eye Health
Study inWestern Australia (n¼ 830; males n¼ 427) and a Chinese
population cohort (n ¼ 1,345; males n ¼ 693) ascertained in Sin-
gapore. White-to-white (WTW)measurements for the study group
were taken with an IOLMaster (Carl Zeiss Meditec) in the Raine
cohort and by Visante measures of anterior of chamber width,
defined as the horizontal distance between the scleral spurs in
the Chinese cohort. WTW measurements and GWAS data were
available for all participants. Individual genotype data forCHRDL1
were extracted from the genome-wide Illumina 660 Quad Array or
610 K array data. Genotyping was performed on an Illumina Bea-
dArray Reader. Samples with call rate below 97% were discarded
from further analysis (Raine cohort 16 samples). SNPs had a call
rate >95%, a Hardy-Weinberg p value less than 5.7 3 107 or
had a minor allele frequency less than 1%. CHRDL1 SNPs assessed
were rs197023, rs12689346, rs5943057, rs12857107. Cross-
sectional analyses of SNP allelic dosage on the WTW measure-
ments were performed with multivariate linear regression adjust-
ing for gender for CHRDL1 SNPs with PLINK version 1.07.
Outcomes were all approximately normally distributed. For non-
normal outcomes, they were log-transformed to normality. Anal-
yses were performed with the statistical graphics software R
version 2.11.1.Fetal Brain Expression Analysis
Raw gene expression data fromhuman fetal brain tissue were gath-
ered from a published study.9 Postmortem specimens from four
late mid-fetal human brains (18, 19, 21, and 23 weeks of gestation)
were collected from the Human Fetal Tissue Repository at the
Albert Einstein College of Medicine (AECOM). Details of speci-
mens, tissue processing, microdissection, and neuropathological
assessment were described elsewhere.9 All samples were originally10, 2012
analyzed by these authors with Affymetrix Exon 1.0 STArrays. The
data set included regional expression data for the striatum, thal-
amus, hippocampus, and nine areas of neocortex, including four
areas of the prefrontal cortex (orbital, dorsolateral, medial, and
ventrolateral prefrontal neocortex), one motor-somatosensory
area, two areas of the temporal cortex (auditory and association
temporal neocortices) and areas from parietal association and
occipital visual neocortices. For our study, cell files from human
fetal specimens were downloaded from the NCBI Gene Expression
Omnibus (accession GSE13344). Background correction, quantile
normalization, log2 transformation and median polishing for
summarization were performed. A full set of probe sets from the
exon-array including core and noncore probe sets were used. Brain
region, date of hybridization and variations due to individual
genetic differences were identified as greater sources of variability
by PCA and therefore included as covariates in the analysis of vari-
ance (ANOVA) to investigate whether CHRDL1 (13 probe sets) and
BMP4 (13 probe sets) were differentially expressed across brain
regions. All exon array data were analyzed with Affymetrix Power
Tools software package (Affymetrix) and Partek Genomics Suite
(Partek).Cognitive Tests
Neuropsychological tests employed were as described previ-
ously.10 All of the standardized tests selected only require verbal
interaction. Intellectual level and executive and memory function
were tested. Details are given in the Supplemental Data.Magnetic Resonance Imaging Acquisition
Control (26 healthy volunteers; 14 males and 12 females, mean
age 42 years, range 22–62 years) and MGC1 subject (two individ-
uals) scans were acquired on the same 3T GE Excite II scanner
(General Electric Medical Systems) with identical scan acquisition
sequences. Standard imaging gradients with a maximum strength
of 40 mT m1 and slew rate of 150 T m1 were used. All data
were acquired with a body coil for transmission and an eight
channel phased array coil for reception. The scanning protocol
included whole-brain T1-weighted and diffusion-weighted scan-
ning. The T1-weighted scan was performed with the following
parameters: two shots, echo time (TE) ¼ 30 ms, repetition time
(TR) ¼ 4,500 ms, matrix 2563 256, 88 contiguous 1.5-mm slices).
Diffusion-weighted images were obtained via spin-echo planar
imaging (EPI) sequence (TE ¼ 73 ms, 60 contiguous 2.4-mm thick
axial slices, matrix size ¼ 96 3 96, voxel size ¼ 1.875 3 1.875 3
2.4 mm3) with 52 noncollinear directions at a b value of
1,200 mm2s-1 (d ¼ 21 ms, D ¼ 29 ms, with full gradient strength
of 40 mT m1) and six nondiffusion-weighted (b ¼ 0) scans.
The gradient directions were calculated and ordered as described
elsewhere.11 The diffusion tensor imaging (DTI) acquisition time
for a total of 3,480 image slices was 25 min, depending on subject
heart rate.Image Analysis: Voxel-Based Morphometry
Differences in total white matter (WM) volume were determined
via voxel-based morphometry (VBM) implemented with SPM5
(Wellcome Trust Center for Neuroimaging, London, UK) with
default parameters. The images were bias-corrected, normalized,
and segmented. Subsequently, the warped WM segments were
affine-transformed into Montreal Neurological Institute (MNI)
space and were scaled by the Jacobian determinants of deforma-
tions to account for the local compression and stretching thatThe Americaoccurs as a consequence of the warping and affine transformation
(modulated WM volumes). Finally the modulated volumes were
smoothed with a Gaussian kernel of 4 mm full-width of half
maximum. The volume maps were statistically analyzed with
a general linear model based on Gaussian random field theory.
Group analysis was performed with a voxel-wise two-sample
t test. Age, gender, and total intracranial volume were included
in the analysis as regressors of no interest.Image Analysis: Tract-Based Spatial Statistics
All scans were transferred to a Linux-based Sun Ultra workstation.
The DICOM files of each DTI acquisition were converted into
a single multivolume ANALYZE 7.5 file and then corrected for
eddy currents with the ‘‘eddy-correct’’ algorithm implemented in
FSL v4.1.3.
Statistical analysis of the fractional anisotropy (FA) values
utilized a tract-based spatial statistics (TBSS) technique from the
Diffusion Toolbox implemented in the FMRIB software, as
described previously.11,12
Briefly, FAmaps from all subjects were aligned to themost repre-
sentative map. A mean FA map was created and aligned into
MNI152 standard space.11,12 The mean FA map was then thinned
to create a mean FA skeleton, representing the main fiber tracts,
and was thresholded at FA> 0.2. Two contrasts for each diffusivity
index were estimated: subjects greater than controls and controls
greater than subjects.Results
Assessment of MGC1 Phenotype in Study Families
We ascertained six new families with MGC1 (Figure 1A). In
family 1, affected individuals II:1 and II:3 had corneal diam-
eters of 16.0 and 15.5 mm, respectively, and large anterior
chamber depths of 6.3 and 7.0 mm (Figure 1E and Table 1).
Central corneal thickness was also markedly reduced in
both individuals (359 mm and 381 mm; Figure 1E and
Table 1). Reported mean values for these ocular parameters
in normal male adult eyes were 11.92 mm (SD ¼ 0.40 mm)
for corneal diameter, 3.15 mm (SD¼ 0.42 mm) for anterior
chamber depth, and 534 mm (SD ¼ 31 mm) for central
corneal thickness (both sexes).13–15 In individuals II:1 and
II:3, mosaic corneal degeneration and corneal arcus juveni-
lis were present and both had bilateral cataract extractions
in their 50s (Figures 1B and 1C and Table 1). Families 2–5
contained a single affected male (age range 8–52 years,
Figure 1 and Table 1). In this latter patient group, corneal
diameters ranged from 15.0 to 16.0 mm, anterior chamber
depth from 5.7 to 7.4 mm (Figure 1D), and central corneal
thickness from 377 to 446 mm (not correlated with age).
Mosaic corneal degeneration and corneal arcus were not
present in the two youngest affected individuals, aged 8
and 9 years (II:1 in family 2 and II:2 in family 3, Figure 1
and Table 1). In family 6, affected individuals III:8 and
V:2 had corneal diameters of 14.0 mm and central corneal
thickness ranging from 437 to 443 mm (Figure 1 and
Table 1). Mosaic corneal degeneration and corneal arcus
were present, even in the youngest individual (V:2, age 16
years). Iris transillumination with pigment dispersion wasn Journal of Human Genetics 90, 247–259, February 10, 2012 249
Figure 1. X-Linked Megalocornea Families and Phenotype
(A) Pedigree structure of six families with X-linked megalocornea (MGC1); family 7 has been described elsewhere (pedigree 1 in Mackey
et al.2). Black boxes denote affected males; dotted circles, carrier females; clear boxes and circles, unaffected individuals.
(B) Right eye of individual II:3 of family 1 showing a greater than average cornea diameter and a white ring at the limbus (arcus juvenilis,
arrow). The superior gap in the iris is from cataract surgery (surgical iridectomy, arrowhead).
(C) Mosaic corneal degeneration of the central corneal stroma (arrowhead) of individual II:1 of family 1.
(D) Axial ultrasound image performed through closed eyelid of the left eye of individual II:2 in family 3 showing a greatly enlarged ante-
rior segment (A), whereas the posterior segment (P) is relatively normal; L is used as an abbreviation of lens.
(E) Optical coherence tomography image of the anterior segment of individual II:1 in family 1 showing thinning of the entire cornea,
limbus to limbus, and a deep anterior chamber. Measurements taken for central corneal thickness, anterior chamber depth, and anterior
chamber diameter are included.detected in all individuals examined. No patient had glau-
coma or a significant visual loss. Individual V:2 in family 6
had significant myopic astigmatism on refraction. No250 The American Journal of Human Genetics 90, 247–259, Februaryneurological or systemic abnormalities were detected for
any affected individuals and carrier females had no clinical
signs of MGC1.10, 2012




Family 1 Family 2 Family 3 Family 4 Family 5 Family 6
II:1 (72) II:3 (67) II:1 (8) II:2 (9) II:1 (15) II:1 (52) III:8 (68) V:2 (16)
Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left






















54 58 53 51 – – – – – – 48 49 33 41 – –
Visual acuity
(LogMAR)
0.3 0.0 0.1 0.1 0.4 0.25 0.2 0.1 0.0 0.0 0.1 0.6b 0.0 0.2 0.18 0.1
Iris
transillumination
þ þ þ þ NA NA þ þ NA NA þ þ NA NA NA NA
Arcus þ þ þ þ – – – – – – þ þ þ þ þ þ




6.8 7.0 6.6 6.3 7.1 7.1 5.9 5.7 6.5 6.3 6.9 7.4 NA NA NA NA
WTW (mm) 16.0 16.0 15.5 15.5 15.5 15.5 15.0 15.0 15.0 15.0 16.0 16.0 14.0 14.0 14.0 14.0
Axial length (mm) 25.7 24.6 25.0 25.0 25.0 24.7 24.2 23.8 25.9 25.9 26.9 26.1 NA NA NA NA
Central corneal
thickness (mm)
359 365 346 381 377 377 428 446 405 408 439 421 438 437 443 442
The following abbreviations and symbols are used: –, not present; NA, not available; WTW, cornea horizontal diameter, white-to-white.





















































Identification of CHRDL1 Mutations Causing MGC1
Using dense X chromosome-specific array comparative
genomic hybridization, we identified a novel segmental
deletion of approximately 250 kb on Xq23 in an affected
male (II:1) from family 1 (Figure 2A). The deletion within
the MGC1 critical interval encompassed the 30 end of
CHRDL1 (Chordin-like 1) and identified CHRDL1 as a candi-
date gene for MGC1 (Figure 2A). To confirm the deletion
and define the deletion breakpoint, we amplified and bidi-
rectionally sequenced the breakpoint fragment (Figure 2B).
The deletion extends proximally 238 kb from intron 5 of
CHRDL1 and segregated with MGC1 in family 1. The junc-
tional sequence showed microhomology between the
proximal and distal breakpoints (Figure 2B). The molecular
mechanism for this deletion could be either nonhomolo-
gous end-joining or a single fork stalling template switch-
ing event.16 CHRDL1 mutation screening in other MGC1
families by exon amplification and direct sequencing iden-
tified frameshift, nonsense, missense, and splice-site muta-
tions inCHRDL1 in the remaining five families (Figure 2C).
The following mutations were identified: a frameshift
mutation in exon 9 (c.872delG [p.Cys291LeufsX25]) in
family 2, a missense mutation in exon 9 (c.782G>T
[p.Cys261Phe]) in family 3, a splice-site mutation in intron
4 (IVS4þ2T>G) in family 4, a frameshift mutation in exon
3 (c.101delAG [p.Glu34AspfsX14]) in family 5, and a
nonsense mutation in exon 8 (c.652C>T [p.Arg218X]) in
family 6 (Figure 2C). Segregation and carrier status were
confirmed and none of the sequence changes were de-
tected in 220 control X chromosomes. In addition to the
six families described, we also screened a previously re-
ported large MGC1 family of Tasmanian origin (Pedigree
1 in Mackey et al.2). In affected individuals, all CHRDL1
exons failed to amplify, indicating a segmental deletion.
The proximal gene RGAG1 was present, and the deletion
was found to extend distally to encompass a 50 alternative
noncoding PAK3 (MIM 300142) exon, which is expressed
in the fetal brain (dbEST, Figure 2D). Interestingly, muta-
tions in PAK3 cause X-linked mental retardation (MIM
300558).17 Important promoter and enhancer sequences
appear to be retained because developmental delay is not
a feature of MGC1. We predict that PAK3 protein expres-
sion in critical brain regions is unaffected by the deletion.
The deletion in the TasmanianMGC1 family spans a region
of 270–600 kb encompassing the entire CHRDL1 gene and
does not share breakpoints with family 1 (Figure 2).
We have shown that in all seven families,MGC1 is caused
by mutation of the CHRDL1 gene (summarized in Table S1,
available online). Segmental deletions, frameshift muta-
tions, and a nonsense mutation are effectively null muta-
tions. The splice-site mutation is predicted to result in
premature termination following intron 4 missplicing. The
predicted functional consequence of themissensemutation
identified in one family (p.Cys261Phe) is discussed below.
Developmental networks of key genes and pathways,
many of which are poorly understood, control vertebrate
eye morphogenesis. Members of the transforming growth252 The American Journal of Human Genetics 90, 247–259, Februaryfactor b (TGFb) superfamily of secreted proteins, including
bonemorphogenicproteins (BMPs), areknowntobe impor-
tant in ocular development.18 For example, mutations in
latent transforming growth factor beta binding protein 2
(LTBP2 [MIM602091]) cause recessive congenital glaucoma
(MIM613086).19 Inheterozygous knockoutTgfb2mice, the
corneal endothelium fails to differentiate and the anterior
chamber never forms.20 Bmp4 heterozygous knockout
mice have anterior segment dysgenesis and elevated intra-
ocular pressure,whereashumanBMP4 (MIM112262)muta-
tions cause a range of syndromic anophthalmia/micro-
phthalmia phenotypes (MIM 607932 and 600625).21,22
Binding of BMPs to their receptors on the cell membrane
activates the Smad1/5/8 transcription factors.23 BMP gradi-
ents are tightly controlled by a network of secreted proteins
that determine the concentration of active BMP ligands.
These regulators include the chordin family of secreted
BMP antagonists. The chordin proteins interact with
BMPsvia conservedcysteine-richdomains,whichare found
in extracellular proteins involved in themodulationof BMP
signaling (Figure S1, available online).23–25 Chordin-like 1
encodes ventroptin (or neuralin-1, neurogenesin-1), which
contains three cysteine-rich domains (von Willebrand
factor C domains).26–28 The missense mutation in family 3
(Cys261Phe) disrupts the first cysteine residue of the third
cysteine-rich domain and is predicted to abrogate the inter-
action of ventroptin and BMPs (Figure S1).
Ventroptin was first identified as an antagonist of BMP
signaling in developing retina and brain.26–28 Ventroptin
acts as an antagonist of Bmp4 and Bmp2 signaling across
the anteroposterior and dorsoventral axes in a double-
gradient manner to modulate the regional specification
of the retina in chick and Xenopus.26,27 In chicks, misex-
pression studies have shown that ventroptin plays a role
in establishing retinal polarity that is important for the
topographic expression of axon guidance molecules and
the formation of the retinotopic map.26 Our genetic
studies establish a previously unidentified requirement
for ventroptin in human anterior segment development.
We therefore examined the expression pattern of CHRDL1
in the developing human eye to delineate spatiotemporal
expression in ocular structures affected by MGC1.
Expression of CHRDL1 in the Developing Human Eye
We detected CHRDL1 expression by RT-PCR in the devel-
oping human cornea, lens, and retina as early as week 7
of gestation (Figure 3A). Expression continues into the
second trimester and persists into adulthood in the cornea
and trabecular meshwork (Figure 3A). In addition to
expression within the developing neural retina, RNA
in situ hybridization revealed CHRDL1 expression in
a distinctive anterior layer of the periocular mesenchyme
that contributes to the development of the structure of
the anterior segment angle and expression in the corneal
stroma and corneal endothelium (Figures 3B–3D, arrow-
heads). These data suggest that lack of ventroptin function
in the anterior neural crest-derived mesenchymal cells of10, 2012
Figure 2. CHRDL1 Mutations Cause X-Linked Megalocornea
(A) X chromosome dense array comparative genomic hybridization for family 1 revealed a deletionwithin the disease interval of approx-
imately 240 kb that encompassed the 30 end of CHRDL1. Genes are schematically represented against the position on the X chromo-
some.
(B) The deletion breakpoint sequence is shown with chromosome X:109726503 joined to sequence chromosome X:109964527
sequence (238,024 bp deleted; hg19 genome build). Microhomology at the deletion breakpoints is highlighted (2 bp; AG).
(C) Schematic of CHRDL1 with patient mutations identified in families 2–6. Nonsense, frameshift, splicing, and missense mutations
were identified in exons 3, 4, 8, and 9. Patient sequence electropherograms are shown above control sequence electropherograms.
(D) Schematic of segmental deletion identified in family 7. The deletion encompasses the entire CHRDL1 gene and extends distally to
PAK3. The first untranslated exon of PAK3 isoforms 206 and 207 (Ensembl nomenclature hg19 genome build) is also deleted.
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Figure 3. CHRDL1 Is Expressed in the Developing Anterior Segment and Cornea
(A) RT-PCR of human eye tissues showing CHRDL1 expression in the developing cornea from week 7 of gestation continuing into adult-
hood. CHRDL1 is also expressed in the developing lens and retina and in adult trabecular meshwork. PAX6 (MIM 607108) was used as
a control.
(B–H) In situ hybridization ofCHRDL1 in the human eye at week 8 of gestation (Carnegie fetal stage F1; sagittal sections) showing expres-
sion in the neural retina (NR), and the anterior periocular mesenchyme (arrowheads) of the developing anterior segment angle and
cornea. The following abbreviations are used: A, anterior segment angle; C, cornea; L, Lens; En, corneal endothelium; St corneal stroma;
Ep, corneal epithelium; LEp, lens epithelium. Sense probe control is shown in (D). The scale bars represent 200 mm (A andD), 100 mm (C),
50 mm (E–G), and 20 mm (H).the anterior segment leads to an increase in corneal diam-
eter and deep anterior chamber.
Is CHRDL1 a Quantitative Trait Locus for Corneal
Diameter?
We speculated that corneal diameter, which is a normally
distributed quantitative trait in the general population,13
might be associated with common CHRDL1 variants. We
evaluated SNPs within introns of CHRDL1 for association
with corneal diameter in two ethnically diverse popula-
tions: the Raine cohort (n ¼ 830), which is 88% white,
and a Chinese population cohort from Singapore (n ¼
1345). No significant association with these CHRDL1 poly-
morphisms was observed (Table S2).
Consequence of Loss of Ventroptin Function on the
Retina and Visual System
Given the potential for an associated asymptomatic retinal
phenotype, on the basis of retinal expression and the254 The American Journal of Human Genetics 90, 247–259, Februaryproposed function of ventroptin, we further explored the
consequences of the lack of functional ventroptin in
MGC1. Detailed clinical examination and retinal and optic
nerve head imaging were undertaken in individuals II:1
and II:3 from family 1 and II:1 from family 5. All three
MGC1 individuals had normal fundi and optic discs,
both clinically and on imaging, and there was no evidence
of an increased cup-to-disc ratio, retinal thinning, or
coloboma (data not shown). Individual V:2 from family 6
(age 16) had macular drusen (data not shown).
We explored the function of the visual system electro-
physiologically. ERGs in individuals II:1 and II:3 from
family 1 showed mildly delayed and subnormal cone
flicker ERGs in keeping with generalized cone system
dysfunction (Figure S2 and Table S3). VEPs were performed
to assess the intracranial visual pathway function. VEPs
have been widely used to investigate maturational and
pathological processes in the visual system. Pattern
reversal VEPs for patient II:3 showed increased peak time10, 2012
in the left hemisphere traces from both eyes indicative of
interhemispheric asymmetry, and there was a delay in
the pattern VEP from the right eye (Figure S2). Pattern
reversal VEPs were delayed from both the right and left
eyes of II:1, but there was no significant interhemispheric
asymmetry in this individual (Figure S2). Analysis of
additional patients will be important to determine the
potential association of a visual pathway or cone system
phenotype with CHRDL1 mutations.
Impact of Loss of Functional Ventroptin on Brain
Function and Morphology
In addition to the previously described role in retinotectal
patterning, ventroptin has a proposed role as a neurogenic
cue in the developing and adult rat brain and in mouse
embryonic cortical and neuronal differentiation, which
require active BMP signaling for neurogenesis.28,29
Although the presence of an interhemispheric VEP asym-
metry does not necessarily indicate a direct relationship
with themutation, given those rodent data, the interhemi-
spheric asymmetry in one MGC1 patient and the observa-
tion that mutations in BMP4 result in cognitive impair-
ment, developmental delay, and structural cerebral
anomalies,30 we hypothesized that loss of ventroptin func-
tion might impact brain function and morphology.
We first examined pre-existing exon expression array
data for 14 brain regions in four human fetal specimens
(18–23 weeks’ gestation) for differential brain expres-
sion.9 From this raw dataset, we extracted data for 13 probe
sets for CHRDL1 exons.9 CHRDL1 was expressed in all
brain regions tested and exhibited regional differential
expression; there was high expression in fetal cerebellum,
frontal, prefrontal, and occipital neocortex (Figure 4A).
Compared to levels of CHRDL1, lower levels of BMP4
were expressed in all regions tested, and there was no
evidence of differential expression (Figure S3).
Neuropsychological tests for intellectual level and exec-
utive and memory function were performed for family 1
individuals II:1 (age 71) and II:3 (age 66). No distinctive
pattern of cognitive deficit was noted. The verbal IQ was
above average with quotients of the 75th (high average
ability) and 99th centile (superior ability). MGC1 patients
also showed superior verbal memory and executive skills
(Table S4). We note that in a clinical MGC1 study pub-
lished in 1942, the cognitive ability of MGC1 was high-
lighted: the proband is described as a quick-witted cockney
workman and his affected grandson had won a scholar-
ship31. Cognitive ability is therefore preserved in the
absence of functional ventroptin.
Next, we explored the impact of loss of ventroptin func-
tion on WM anatomy. We compared WM volume of 26
healthy volunteers with the volume of individuals II:1
and II:3 from family 1. VBM showed loss of WM (p ¼
0.01, false discovery rate correction, cluster ¼ 100 voxels)
in the body and genus of the corpus callosum and symmet-
rically in the internal capsule, inferior fronto-occipital
fasciculus, inferior longitudinal fasciculus, dorsal andThe Americaventral mesencephalon, and ventral portions of the pons
and cerebellum (Figure 4B). After more conservative correc-
tion for multiple testing (p < 0.05, familial-wise error
correction), clusters in the body of the corpus callosum,
the dorsal portion of the mesencephalon, and the left
middle cerebellar peduncle remained significant
(Figure 4C). MR tractography provides a measure of WM
tract integrity. FA is a measure that reflects microstructural
properties of the WM, including axon diameter, myelina-
tion, and fiber density.32 Group comparison of FA values
with tract-based spatial statistics revealed lower FA values
in MGC1 patients compared to the values in controls
(p < 0.05, noncorrected) in the same WM regions that
were found to have significantly reduced WM volume by
the VBM analyses (Figure 4D). No regions with higher FA
were found in subjects compared to values in controls.Discussion
Regulation of BMP signaling is important for both
patterning and control of organ size during embryogenesis
and is tightly controlled by extracellular and intracellular
mechanisms. BMPs can form homo- or heterodimers,
which are thought to facilitate variable interactions with
receptors and activation of different signaling pathways.
Both types of BMP receptors (type I and type II) are required
to form a functional heteromeric complex and initiate
downstream signaling.33 Receptor-BMP ligand binding
activates either the canonical BMP signaling pathway (acti-
vation of SMAD transcription factors) or the noncanonical
BMP signaling pathway (MAPK pathway). BMP signaling is
regulated in part by the spatiotemporal expression gradi-
ents of BMPs and their receptors but also through the
spatiotemporal expression of extracellular BMP antagonists
with variable binding affinities for BMPs. BMP signaling
can also be modulated by intracellular mechanisms (e.g.,
inhibitory SMADs).33 The BMP signaling pathway is further
complicated by crosstalk with Wnt and Sonic hedgehog
signaling during development.33
Reduced BMP signaling caused by mutations in BMP4 is
themechanism described as underlying human syndromic
anophthalmia/microphthalmia phenotypes.22,30 In con-
trast to the reduced ocular organ size observed in these
conditions, lack of functional extracellular BMP antagonist
ventroptin described here causes an increase in anterior
segment size. Although the precise mechanism remains to
be determined, we hypothesize that in the absence of func-
tional ventroptin, the tightly regulated gradient of BMPs is
perturbed, leading to dysregulation of BMP signaling (via
BMP4 and/or other BMPs) and subsequent misexpression
of downstream genes. This could result from either BMP
overactivity caused by loss of the inhibitory function of
ventroptin or the loss of the restricted BMP expression
gradient in specific ocular tissues during development.
This hypothesis is supported by a study describing a chor-
din knockoutmouse.34Chordin is a related BMPantagonistn Journal of Human Genetics 90, 247–259, February 10, 2012 255
Figure 4. Lack of Ventroptin Function Results in Loss of White Matter or Tract Integrity in Specific Brain Regions
(A) CHRDL1 is differentially expressed in fetal brain regions. Pooled data for four fetal human brains (18, 19, 21, and 23 weeks of gesta-
tion) and 13 probes covering CHRDL1 exons are shown for specific brain regions (x axis) on a Log2 scale (y axis). CHRDL1 is expressed in
all brain regions tested, with highest expression in cerebellum and neocortex. The following abbreviations are used: F_ms, motor
somatosensory neocortex; PreF, prefrontal cortex (orbital dorsolateral, medial and ventrolateral prefrontal neocortex); Par, parietal asso-
ciation neocortex; Occ, occipital visual neocortex; T_aud, temporal auditory neocortex; T_ass, temporal association neocortex; Hipp,
hippocampus; Str, striatum; Thal, mediodorsal thalamus; Cbl, cerebellum. Box plots represent median and 25th–75th percentiles. Upper
and lower lines show minimum and maximum values, respectively.
(B and C) White matter volume is reduced in patients lacking ventroptin function. (B) voxel-based morphometry showing focal white
matter volume reductions (color code red, false discovery rate, p < 0.05, cluster size R 100) and (C) white matter volume reductions
(color coded yellow and highlighted with arrows) after family-wise error correction (FWE, p ¼ 0.05, T > 7.4).
(D) Significant fractional anisotropy (FA) decrease in specific brain regions. Tract-based spatial statistics were superimposed on the
MNI152 template. Significant FA decrease was observed compared to values in healthy controls. The color scaled red to yellow shows
the group skeleton (without difference in FA value); the color green indicates skeletal voxels with a significant FA reduction of at least
p ¼ 0.05 (noncorrected).expressed in many tissues throughout development. Inter-
estingly, surviving chordin-null mice were found to have
a significant increase in presynaptic transmitter release
from hippocampal neurons and altered cognitive behavior
including a significantly enhanced learning rate in Morris
water maze tests. These data support the hypothesis that
BMP signaling regulates synaptic function in the presyn-
aptic terminal. Perfusion of BMP ligands onto hippocampal
slices replicated the presynaptic phenotype of the chordin-
null mouse and the authors suggest that enhanced BMP256 The American Journal of Human Genetics 90, 247–259, Februarysignaling in the absence of chordin is the mechanism that
results in enhanced short-term plasticity and spatiotem-
poral processing.34
Intriguingly, these data in chordin knockout mice
appear to correlate with the observed high performance
in tests of memory in our two MGC1 subjects, despite
a striking focal loss of WM. This suggests that chordin
and ventroptin have functionally similar effects on BMP
signaling; chordin primarily exerts its’ inhibitory effects
on the hippocampus, and ventroptin on the hippocampus10, 2012
and prefrontal brain regions. None of our MGC1 cases has
developmental or cognitive problems, which also suggests
that loss of WM and tract integrity does not compromise
brain function. Studies of cerebral WM development in
human neonates and infants in vivo generally show an
increase in the degree of anisotropy with maturation.32
These diffusion changes are linked to a concomitant
increase in myelination, reduction in brain water, greater
cohesiveness and compactness of fiber tracts, and reduced
extra-axonal space (i.e., greater packing) as WM matures
over time.35 Changes in diffusion anisotropy in MGC1
might be caused by loss of BMP inhibition by ventroptin,
and therefore loss of oligodendrocytic differentiation and
myelination; disorganization or maldevelopment of the
fiber tracts could be another explanation for the observed
lower FA in our MGC1 patients. Several studies have
shown that overexpression of BMPs inhibits oligodendro-
cyte development and myelin protein expression, which
suggests an inhibitory effect of enhanced BMP
signaling.36,37,38 This supports the idea that the changes
in diffusion anisotropy in MGC1 patients are caused by
loss of oligodendrocytic differentiation and myelination
as a result of enhanced BMP signaling in the absence of
functional ventroptin.
Overexpression of Chrdl1 results in altered projection of
retinal axons to the tectum along the anteroposterior and
dorsoventral axes in chick.25 Our findings in humans also
suggest that anatomical connectivity of the visual system
mightbealtered, especially in themesencephalon.Although
CHRDL1 appearswidely expressed in the developinghuman
brain, the consequences of mutation for the brain are both
spatially and functionally limited. Redundancy and
compensatory changes might underlie this resilience, but
the full phenotype of CHRDL1 mutation likely extends
beyond the eye. Our current extraocular data are limited to
two relatedMGC1 patients, such that the complex anatom-
ical and neurosychological features could be associated with
other common alleles in essential genes expressed in the
brain. It will be important to recruit new patients with this
rare condition for similar studies to definitively link these
observed phenotypes with mutations in the CHRDL1 gene.
We show that MGC1 is genetically homogeneous, as all
cases studied are caused by mutation of the CHRDL1 gene.
Wealsodemonstrate thatCHRDL1 is expressed in thedevel-
oping humanperiocularmesenchyme, corneal stroma, and
corneal endothelium, delineating MGC1 as a neural crest-
derived anterior segment disorder. Because CHRDL1 is ex-
pressed in the developing human retina and ventroptin
has a proposed role in retinotectal patterning, we explored
the potential for an asymptomatic retinal or visual pathway
phenotype in MGC1 patients. Intriguingly, mild cone
photoreceptor system dysfunction was observed in two
related subjects and suggestive occipital interhemispheric
asymmetry in one subject. Although other affected individ-
uals need to be tested before conclusions can be drawn,
these results might represent asymptomatic MGC1 pheno-
types associated with lack of ventroptin function caused byThe Americaa similar mechanism of enhanced and aberrant spatiotem-
poral BMP signaling interfering with tightly regulated neu-
rodevelopment or synaptic functional maturation.Supplemental Data
Supplemental Data include three figures and four tables and can
be found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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